全文获取类型
收费全文 | 256篇 |
免费 | 21篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 3篇 |
基础医学 | 40篇 |
口腔科学 | 5篇 |
临床医学 | 26篇 |
内科学 | 48篇 |
皮肤病学 | 3篇 |
神经病学 | 11篇 |
特种医学 | 11篇 |
外科学 | 37篇 |
预防医学 | 16篇 |
眼科学 | 15篇 |
药学 | 12篇 |
肿瘤学 | 49篇 |
出版年
2023年 | 1篇 |
2022年 | 4篇 |
2021年 | 5篇 |
2020年 | 2篇 |
2019年 | 3篇 |
2018年 | 9篇 |
2017年 | 1篇 |
2016年 | 7篇 |
2015年 | 9篇 |
2014年 | 3篇 |
2013年 | 17篇 |
2012年 | 18篇 |
2011年 | 16篇 |
2010年 | 7篇 |
2009年 | 5篇 |
2008年 | 14篇 |
2007年 | 13篇 |
2006年 | 10篇 |
2005年 | 12篇 |
2004年 | 11篇 |
2003年 | 14篇 |
2002年 | 6篇 |
2001年 | 17篇 |
2000年 | 12篇 |
1999年 | 10篇 |
1998年 | 3篇 |
1997年 | 3篇 |
1996年 | 1篇 |
1995年 | 2篇 |
1994年 | 1篇 |
1992年 | 7篇 |
1991年 | 8篇 |
1990年 | 2篇 |
1989年 | 3篇 |
1988年 | 4篇 |
1987年 | 1篇 |
1986年 | 3篇 |
1985年 | 3篇 |
1984年 | 1篇 |
1979年 | 3篇 |
1975年 | 2篇 |
1971年 | 2篇 |
1970年 | 1篇 |
1969年 | 1篇 |
排序方式: 共有277条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
G Simone A Paradiso R Cirillo A Mangia G Rella S Wiesel S Petroni G De Benedictis M De Lena 《Pathologica》1991,83(1086):449-459
Recently, a method similar to ER.ICA has been proposed for the progesterone receptor (PgR) using two monoclonal antibodies, JZB39 and KD68, specific for human PgR and characterized by a molecular weight of 95 and 120 Kd, respectively. A series of 73 breast cancer patients was studied with regards to ER and PgR using both immunocytochemical (ICA) and biochemical (DCC) assays. Results showed no substantial differences between the two methods when considering common clinical-pathological parameters. Overall agreement between ICA and DCC methods was found: 79% for PgR and 78% for ER. A slight quantitative correlation was also observed between the "score values" of the ICA method and the Fmol content of ER and PgR using the Brave-Pearson test (r = 0.49 for PgR; r = 0.43 for ER). Specificity of PgR.ICA method was 77% for PgR and 72% for ER; sensitivity was 82% and 83%, respectively. The ICA method is a reliable technique to assess PgR presence as well as ER. Further studies are necessary to evaluate the prognostic role of nuclear PgR. 相似文献
5.
Marco Aurélio Petroni Montezuma Felipe Paiva Fonseca Bernar Monteiro Benites Ciro Dantas Soares Gleyson Kleber do Amaral-Silva Oslei Paes de Almeida Fernando Augusto Soares Rosana Lima Pagano Eduardo Rodrigues Fregnani 《Pathology, research and practice》2018,214(6):907-913
Ameloblastoma is a locally aggressive neoplasm with a poorly understood pathogenesis. Therefore, the aim of this study is to investigate whether COX-2 expression is associated with ameloblastoma microvascular density (MVD) and with tumor aggressiveness. Sixty-three cases of primary ameloblastomas arranged in tissue microarray were submitted to immunohistochemistry against cyclooxigenase-2 (COX-2) and CD34. Clinicopathological parameters regarding sex, age, tumour size, tumour duration, tumour location, treatment, recurrences, radiographic features, vestibular/lingual and basal cortical disruption and follow-up data were obtained from patients’ medical records and correlated with the proteins expression. The results on BRAF-V600E expression were obtained from our previous study and correlated with COX-2 and CD34 expressions. Log-rank univariate analysis and multivariate Cox regression model were done to investigate the prognostic potential of the molecular markers. Twenty-eight cases (44.4%) exhibited cytoplasmic positivity for COX-2, predominantly in the columnar peripheral cells, with a mean MVD of 2.2 vessels/mm2. COX-2 was significantly associated with recurrences (p?<?0.001) and BRAF-V600E expression (p?<?0.001), whereas lower MVD was associated with the use of conservative therapy (p?=?0.004). Using univariate and multivariate analyses, COX-2 was significantly associated with a lower 5-year disease-free survival (DFS) rate (p?<?0.001 and p?=?0.012, respectively), but not with a higher MVD (p?=?0.68). In conclusion, COX-2 expression in ameloblastomas is not associated with MVD, but it is significantly associated with recurrences and with a lower DFS. 相似文献
6.
7.
Albani G Petroni ML Mauro A Liuzzi A Lezzi G Verti B Marzullo P Cattani L 《Journal of gastroenterology》2005,40(8):833-835
Background Botulin toxin (BTX) has been proposed as a potential obesity treatment.Methods In a pilot study, the short-term efficacy and safety of BTX was assessed in eight subjects (four men, four women; median age, 46 years; range, 35–57 years) with severe obesity (median body mass index [BMI], 47.1 kg/m2; range 38.2–56.7 kg/m2) and multiple dietary treatment failures. In a single endoscopic session, 500 UI of BTX-A was injected in the gastric antral region.Results No clinically significant side effects were observed. In all patients, despite their not being on a specific diet, a reduction of body weight was observed at 1 month (median baseline weight, 124.4 kg vs 121.8 kg at 1 month; P < 0.05). Two treatment-unrelated dropouts were observed. At 4 months, three of the six patients had a further weight loss. The treatment effect was apparently independent of changes in hunger or satiety, or of changes in fasting and postprandial plasma ghrelin and serum leptin, thus suggesting a different pharmacological mechanism.Conclusions BTX-A treatment appears to be safe and well tolerated by obese patients, while its short-term efficacy varied widely. 相似文献
8.
9.
10.